PDCD6

Across TCGA pan-cancer cohorts, PDCD6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDCD6 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PDCD6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDCD6 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where PDCD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.577	0.867	.001	41	view →
UCEC	OS	Median	II,III,IV	0.609	1.000	.008	24	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	10	view →
LSCC	OS	Quartile	III,IV	0.670	1.000	.030	5	view →
GBM	OS	Quartile	All	0.662	0.466	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDCD6–CCRCC (DFS)

Open the CCRCC breakdown →